Clinical Trials Browser

INDUSTRY × Carcinoma, Non-Small-Cell Lung × ensartinib × Clear all

NCT01625234 2026-04-30

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Phase 1/2 Completed

131 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02767804 2025-10-14

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Phase 3 Active not recruiting

290 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05341583 2024-08-23

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03215693 2023-08-16

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04146571 2022-10-20

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04415320 2020-06-04

X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Phase 2 Unknown

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03510611 2019-07-24

A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung